Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Open in Screener

CELU

Celularity Inc

Oct 22 • 04:00PM ET

2.14

Dollar change +0.04
Percentage change 1.88	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP EDIT FATE ADVM NTLA SAGE BLUE CARA SANA KPTI

| Held by: VTI VXF IWC DFAC DFSU

Index	-	P/E	-	EPS (ttm)	-8.23	Insider Own	51.28%	Shs Outstand	19.38M	Perf Week	-23.95%
Market Cap	47.14M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	10.71M	Perf Month	-25.53%
Income	-154.29M	PEG	-	EPS next Q	-	Inst Own	11.30%	Short Float	6.34%	Perf Quarter	-28.56%
Sales	33.52M	P/S	1.41	EPS this Y	-	Inst Trans	4.62%	Short Ratio	41.98	Perf Half Y	-33.19%
Book/sh	1.43	P/B	1.50	EPS next Y	-	ROA	-60.96%	Short Interest	0.68M	Perf Year	-9.17%
Cash/sh	0.09	P/C	24.81	EPS next 5Y	-	ROE	-165.13%	52W Range	1.59 - 7.97	Perf YTD	-13.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-718.48%	ROI	-268.29%	52W High	-73.09%	Beta	0.44
Dividend TTM	-	Quick Ratio	0.29	Sales past 5Y	12.07%	Gross Margin	26.10%	52W Low	34.88%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	0.35	EPS Y/Y TTM	-748.86%	Oper. Margin	-162.19%	RSI (14)	33.52	Volatility	16.59% 10.54%
Employees	120	Debt/Eq	2.11	Sales Y/Y TTM	109.81%	Profit Margin	-460.34%	Recom	1.00	Target Price	25.00
Option/Short	Yes / Yes	LT Debt/Eq	0.84	EPS Q/Q	75.08%	Payout	-	Rel Volume	3.18	Prev Close	2.11
Sales Surprise	-42.97%	EPS Surprise	-70.83%	Sales Q/Q	273.09%	Earnings	-	Avg Volume	16.18K	Price	2.14
SMA20	-18.94%	SMA50	-23.38%	SMA200	-37.70%	Trades		Volume	50,290	Change	1.88%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$5 → $1
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jun-22-22	Initiated	H.C. Wainwright	Buy	$15
Apr-06-22	Downgrade	Truist	Buy → Hold	$10
Jan-28-22	Initiated	Oppenheimer	Outperform	$9
Nov-24-21	Initiated	Morgan Stanley	Equal-Weight	$9

Oct-22-24 08:30AM	Celularity Provides Corporate Update (GlobeNewswire)
Oct-18-24 06:00PM	Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal (GlobeNewswire) -16.14%
Oct-16-24 05:15PM	Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound Product from Sequence LifeScience, Inc. (GlobeNewswire) -6.47%
Sep-05-24 04:05PM	Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference (GlobeNewswire)
Aug-28-24 04:45PM	Celularity Appoints Richard J. Berman to its Board of Directors (GlobeNewswire)
05:00PM	Loading…
Aug-23-24 05:00PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing (GlobeNewswire)
Jul-31-24 08:30AM	Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023 (GlobeNewswire) +5.35%
Jun-03-24 08:38AM	Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-24-24 05:15PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing (GlobeNewswire)
May-14-24 09:15AM	Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy (GlobeNewswire) +25.95%
Apr-22-24 08:00AM	Celularity Inc. to Host Investor and Analyst Research & Development Day (GlobeNewswire)
Apr-19-24 05:30PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing (GlobeNewswire) -5.61%
Apr-18-24 04:30PM	Celularity Abstract Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials Accepted at ORS Tendon Conference 2024 (GlobeNewswire)
Apr-15-24 08:00AM	Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products (GlobeNewswire)
Apr-08-24 09:00AM	Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells (GlobeNewswire)
09:00AM	Loading…
Mar-26-24 09:00AM	Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L (GlobeNewswire)
Mar-20-24 09:15AM	Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy (GlobeNewswire)
Mar-14-24 09:15AM	Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit (GlobeNewswire)
Mar-12-24 09:20AM	Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress (GlobeNewswire) -15.30%
Mar-07-24 09:35AM	Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells (GlobeNewswire) +27.67%
Feb-23-24 04:10PM	Celularity Announces 1-for-10 Reverse Stock Split (GlobeNewswire) +7.13% -9.56%
Feb-14-24 04:05PM	Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease (GlobeNewswire)
Feb-01-24 09:00AM	Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline (GlobeNewswire) +28.45%
Jan-25-24 09:00AM	Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions (GlobeNewswire) +16.00%
Jan-18-24 01:40PM	Celularity Releases CEO Letter to Shareholders (GlobeNewswire) +53.48%
Jan-04-24 01:00PM	Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare (GlobeNewswire) -9.25%
Jan-03-24 07:30PM	BioCellgraft Finalizes Commercialization Agreement with Celularity For The Manufacture and Distribution of Products for Therapeutic Use in Oral Healthcare (PR Newswire)
12:00PM	Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 (GlobeNewswire)
Nov-24-23 01:15PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing (GlobeNewswire)
Oct-18-23 09:00AM	Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification (GlobeNewswire) -8.35%
04:10PM	Loading…
Sep-07-23 04:10PM	Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Aug-29-23 09:00AM	Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron (GlobeNewswire) +8.04%
Jul-27-23 09:07AM	Celularity Inc. Announces $3 Million Registered Direct Offering (GlobeNewswire) +9.57%
09:00AM	Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications (GlobeNewswire)
Jul-18-23 09:00AM	Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies (GlobeNewswire) +5.71%
Jun-29-23 04:05PM	Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics (GlobeNewswire) +5.89%
Jun-01-23 09:15AM	Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability (GlobeNewswire) -8.71%
May-23-23 10:56AM	CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS (PR Newswire)
May-19-23 04:21PM	Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohns Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation (GlobeNewswire) +11.27%
May-10-23 09:00AM	Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products (GlobeNewswire) +10.18%
May-01-23 04:01PM	Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy (GlobeNewswire) -8.79%
Apr-27-23 09:00AM	Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia (GlobeNewswire)
Apr-12-23 09:00AM	Celularitys Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference Beyond Longevity: Live 120 Like 50 (GlobeNewswire)
Apr-05-23 09:00AM	Celularity Inc. Announces $6 Million Registered Direct Offering (GlobeNewswire) -11.48%
Apr-04-23 09:00AM	Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting (GlobeNewswire)
Apr-03-23 09:00AM	Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularitys Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDAs Center For Devices And Radiological Health (GlobeNewswire) +19.41%
Mar-28-23 10:55AM	Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt (PR Newswire)
09:00AM	Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt (GlobeNewswire)
Feb-02-23 07:53AM	Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) (GlobeNewswire)
Feb-01-23 04:05PM	Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) (GlobeNewswire) +8.50%
Jan-26-23 04:17PM	Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates (GlobeNewswire) +7.68%
Jan-11-23 01:35PM	Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East (PR Newswire) +13.21%
01:22PM	Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia (PR Newswire)
Jan-06-23 08:10AM	Celularitys Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohns Disease in Phase 1, Phase 1b/2a and Phase 1b Studies (GlobeNewswire)
Jan-04-23 04:10PM	Celularity Appoints Paul Graves as Chief Communications Officer (GlobeNewswire) -14.15%
Dec-05-22 08:00AM	Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model (Business Wire)
Nov-30-22 09:55AM	Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on "The Science and Technology for Extending Healthy Human Lifespan" (Business Wire)
Nov-10-22 05:00PM	Imugenes onCARlytics combination with Celularitys placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting (GlobeNewswire) +14.52%
04:10PM	Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
09:10AM	Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancers 37th Annual Meeting (GlobeNewswire)
Oct-06-22 08:00AM	Celularity Promotes Two Executives in Executive Leadership Team (GlobeNewswire)
Oct-03-22 08:00AM	Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer (GlobeNewswire) -5.19%
Sep-27-22 08:00AM	Celularity to Present at Jefferies Cell and Genetic Medicine Summit (GlobeNewswire)
Sep-26-22 08:00AM	Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro (GlobeNewswire)
Sep-15-22 02:29PM	Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville (GlobeNewswire) -8.90%
Sep-06-22 04:10PM	Celularity Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-09-22 04:10PM	Celularity Reports Second Quarter 2022 Financial Results and Corporate Update (GlobeNewswire)
Jul-27-22 08:00AM	Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers (GlobeNewswire) -10.89%
Jul-04-22 10:08AM	Celularity (NASDAQ:CELU) shareholders have endured a 65% loss from investing in the stock a year ago (Simply Wall St.)
Jun-08-22 04:10PM	Celularity To Be Added To The Russell 3000® Index And The Small-Cap Russell 2000® (GlobeNewswire) -16.26%
Jun-03-22 08:00AM	Celularity Appoints Industry Leader Diane Parks to its Board of Directors (GlobeNewswire)
May-18-22 08:30AM	Celularity Inc. Announces $30 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
May-16-22 04:10PM	Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -12.53% +17.76%
Mar-31-22 04:05PM	Celularity Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-15-22 04:05PM	Celularity to Present at Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
12:59PM	What Percentage Of Celularity Inc. (NASDAQ:CELU) Shares Do Insiders Own? (Simply Wall St.)
Feb-15-22 04:05PM	Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers (GlobeNewswire) +8.36% +8.39%
Jan-27-22 05:38PM	C V Starr & Co Inc Buys Celularity Inc (GuruFocus.com) -6.47% +9.23%
05:38PM	Starr International Co Inc Buys Celularity Inc, Sells Moderna Inc, AstraZeneca PLC, Johnson ... (GuruFocus.com)
Jan-18-22 08:00AM	Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers (GlobeNewswire) -7.97%
Dec-27-21 08:00AM	Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML (GlobeNewswire) +6.60%
Dec-15-21 09:04AM	Analysts' Revenue Estimates For Celularity Inc. (NASDAQ:CELU) Are Surging Higher (Simply Wall St.)
Dec-13-21 08:00AM	Celularity Presents Preclinical Data on Allogeneic Genetically Modified Natural Killer (NK) and Allogeneic CAR-NK Cell Therapy Programs at the 63rd American Society of Hematology Meeting and Exposition (GlobeNewswire) -7.61%
Nov-29-21 08:00AM	Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer (GlobeNewswire)
Nov-16-21 05:35AM	Celularity (NASDAQ:CELU) investors are sitting on a loss of 34% if they invested a year ago (Simply Wall St.) +5.73%
Nov-15-21 08:00AM	Celularity Presents Preclinical Data on Allogeneic Genetically-Modified Natural Killer Cells at the Society for Immunotherapy of Cancer 36th Annual Meeting (GlobeNewswire)
Nov-12-21 04:05PM	Celularity Reports Third Quarter 2021 Financial Results and Corporate Update (GlobeNewswire)
Sep-20-21 08:00AM	Oncternal Therapeutics and Celularity Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies (GlobeNewswire)
08:00AM	Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies (GlobeNewswire)
Aug-16-21 05:15PM	Celularity Reports Second Quarter 2021 Financial Results (GlobeNewswire) -5.38% +11.38%
Aug-04-21 07:00PM	Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors (GlobeNewswire) -7.73%

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lim Kok Thay	10% Owner	Jan 12 '24	Buy	0.25	21,410,983	5,331,335	51,473,762	Jan 17 05:22 PM

Open in Screener

SCLX

Scilex Holding Company

Oct 22 • 04:00PM ET

0.9704

Dollar change -0.0096
Percentage change -0.98	%

Healthcare • Drug Manufacturers - General • USA • NASD

SCLX Scilex Holding Company daily Stock Chart

Peers: TEVA BHC PRGO RDY AMPH EGRX PFE ABBV MRK NBIX

| Held by: XBI VTI VXF VTI IWM VXF LABU IWN JSML VHT

Index	-	P/E	-	EPS (ttm)	-1.02	Insider Own	39.41%	Shs Outstand	191.79M	Perf Week	20.10%
Market Cap	186.11M	Forward P/E	-	EPS next Y	-0.39	Insider Trans	0.45%	Shs Float	116.21M	Perf Month	23.40%
Income	-118.89M	PEG	-	EPS next Q	-0.14	Inst Own	20.92%	Short Float	9.53%	Perf Quarter	-43.25%
Sales	50.83M	P/S	3.66	EPS this Y	46.09%	Inst Trans	38.70%	Short Ratio	9.54	Perf Half Y	-0.65%
Book/sh	-1.77	P/B	-	EPS next Y	43.00%	ROA	-102.93%	Short Interest	11.08M	Perf Year	-40.83%
Cash/sh	0.04	P/C	27.01	EPS next 5Y	-	ROE	-	52W Range	0.73 - 2.63	Perf YTD	-52.43%
Dividend Est.	-	P/FCF	15.27	EPS past 5Y	-	ROI	-	52W High	-63.10%	Beta	1.17
Dividend TTM	-	Quick Ratio	0.19	Sales past 5Y	14.78%	Gross Margin	60.16%	52W Low	32.64%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	0.20	EPS Y/Y TTM	-62.41%	Oper. Margin	-195.02%	RSI (14)	53.23	Volatility	18.77% 12.08%
Employees	105	Debt/Eq	-	Sales Y/Y TTM	119.45%	Profit Margin	-233.88%	Recom	1.00	Target Price	9.88
Option/Short	Yes / No	LT Debt/Eq	-	EPS Q/Q	-67.40%	Payout	-	Rel Volume	4.13	Prev Close	0.98
Sales Surprise	5.94%	EPS Surprise	-53.73%	Sales Q/Q	30.11%	Earnings	Aug 28	Avg Volume	1.16M	Price	0.97
SMA20	9.99%	SMA50	-4.93%	SMA200	-28.38%	Trades		Volume	4,534,494	Change	-0.98%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-24	Initiated	Alliance Global Partners	Buy	$14
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$13
Oct-16-23	Initiated	B. Riley Securities	Buy	$4
Oct-13-23	Initiated	B. Riley Securities	Buy	$4
Oct-09-23	Initiated	H.C. Wainwright	Buy	$12

Oct-16-24 07:00AM	Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential (GlobeNewswire) +7.67%
04:00AM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion (GlobeNewswire)
Oct-08-24 01:58PM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024 (GlobeNewswire) -8.34%
11:50AM	Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing (GlobeNewswire)
Oct-07-24 10:00AM	Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt (PR Newswire) -6.55%
09:52AM	Loading…
09:52AM	Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile (GlobeNewswire)
Sep-26-24 09:00AM	Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025 (GlobeNewswire) +12.51%
Sep-18-24 09:00AM	Scilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex's Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan (GlobeNewswire)
Sep-12-24 09:00AM	Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy (NABP ) (GlobeNewswire)
Sep-09-24 09:00AM	Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference (GlobeNewswire)
Sep-05-24 09:00AM	Scilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 19, 2024 (GlobeNewswire)
Sep-03-24 09:00AM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination (GlobeNewswire)
09:00AM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion (GlobeNewswire)
Aug-30-24 09:00AM	Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024 (GlobeNewswire)
Aug-29-24 09:00AM	Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA Label (GlobeNewswire)
09:00AM	Loading…
Aug-21-24 09:00AM	Scilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB Patent Related to the Treatment of Acute Pain (GlobeNewswire)
Aug-09-24 09:00AM	Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa (GlobeNewswire)
Aug-01-24 09:00AM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024 (GlobeNewswire) -5.66%
Jul-24-24 10:52AM	Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report (GlobeNewswire)
Jul-23-24 09:00AM	Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D. (GlobeNewswire)
Jul-17-24 09:00AM	Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics' R&D Expertise and Local Market Connections to Support the Expansion of ZTlido Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region (GlobeNewswire)
Jul-03-24 07:21AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.74%
Jul-02-24 05:15PM	Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination (GlobeNewswire)
09:00AM	Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York (GlobeNewswire)
Jul-01-24 09:00AM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024 (GlobeNewswire)
Jun-20-24 09:00AM	Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC. (GlobeNewswire) +7.10%
Jun-14-24 01:41PM	Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA ) in Lumbosacral Radicular Pain (Sciatica) (GlobeNewswire) +8.05%
Jun-13-24 09:00AM	Scilex Holding Company to Present Poster on ELYXYB (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024 (GlobeNewswire)
Jun-11-24 07:20PM	Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies (GlobeNewswire) +18.75% +8.27%
09:00AM	Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA (GlobeNewswire)
11:49AM	Loading…
Jun-10-24 11:49AM	Scilex Holding Company Announces Stocking of GLOPERBA is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S. (GlobeNewswire)
Jun-06-24 02:56PM	Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba which will be launched in the US in the week of June 10th 2024 (GlobeNewswire) +9.26%
May-30-24 01:19PM	Scilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company (GlobeNewswire)
May-24-24 01:40PM	Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index (GlobeNewswire)
09:00AM	Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company (GlobeNewswire)
May-14-24 09:00AM	Scilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba (GlobeNewswire)
08:53AM	SCLX Stock Earnings: Scilex Holding Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-13-24 09:00AM	Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock (GlobeNewswire) +7.98%
Apr-25-24 04:01PM	Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering (GlobeNewswire)
Apr-24-24 08:00AM	Scilex Holding Company Announces $15 Million Registered Direct Offering (GlobeNewswire) -12.97%
Apr-16-24 09:00AM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses (GlobeNewswire) -9.38%
Apr-09-24 09:00AM	Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool (GlobeNewswire)
Mar-27-24 09:00AM	Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend (GlobeNewswire) +6.62%
Mar-21-24 09:30AM	Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients (GlobeNewswire)
Mar-20-24 11:00AM	Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed (GlobeNewswire)
09:00AM	Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba (GlobeNewswire)
Mar-19-24 09:00AM	Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation (GlobeNewswire)
Mar-18-24 09:00AM	Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB for Acute Treatment of Migraine With or Without Aura in Canada (GlobeNewswire)
Mar-15-24 02:45PM	Scilex Holding Announces Issuance of Halal Certification for its ZTlido product by Circle H International, Inc. (GlobeNewswire)
09:00AM	Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement (GlobeNewswire)
Mar-05-24 04:01PM	Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering (GlobeNewswire)
09:00AM	Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba , its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024 (GlobeNewswire)
Mar-04-24 09:00AM	Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates (GlobeNewswire)
Mar-02-24 03:25PM	Scilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024 (GlobeNewswire)
Feb-29-24 05:32PM	Scilex Holding Company Announces $10 Million Bought Deal Offering (GlobeNewswire) -6.20% -41.19%
Feb-28-24 09:00AM	Scilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA in Most of Their Stores Throughout the U.S. (GlobeNewswire)
Feb-27-24 09:00AM	Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM) (GlobeNewswire) +11.59%
Feb-26-24 04:53PM	Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement (GlobeNewswire) +18.29%
09:00AM	Scilex Holding Company Announces that ZTlido Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met (GlobeNewswire)
Feb-20-24 09:00AM	Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido for the Treatment of Chronic Neck Pain (GlobeNewswire)
Jan-08-24 09:00AM	Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024 (GlobeNewswire)
Jan-02-24 09:00AM	Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information (GlobeNewswire)
Dec-26-23 11:00AM	Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB for Acute Treatment of Migraine With or Without Aura in Canada (GlobeNewswire) +15.71%
Dec-20-23 09:00AM	Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists (GlobeNewswire) -7.14%
Dec-19-23 09:00AM	Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba as a Liquid Colchicine Formulation Designed for Precision Dosing (GlobeNewswire) +11.11%
Dec-15-23 09:00AM	Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB in most of their stores throughout the U.S. (GlobeNewswire) +8.59%
Dec-12-23 09:00AM	Scilex Holding Company Announces Expanded Access to ELYXYB By the Execution of First ELYXYB Insurance Coverage Agreement with One of the Top Three National PBMs (Pharmacy Benefit Manager) for its Medicare Population (GlobeNewswire)
Dec-06-23 09:00AM	Scilex Holding Company announces that ZTlido (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State (GlobeNewswire)
Dec-04-23 09:00AM	Scilex Holding Company announces the addition of ZTlido® (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee (GlobeNewswire)
09:00AM	Scilex Holding Company announces the addition of ZTlido (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List of the State of Tennessee (GlobeNewswire)
Dec-01-23 09:00AM	Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended November 2023, And Year-To-Date Through November 30, 2023, Based On Currently Available Information (GlobeNewswire) +8.00%
Nov-30-23 09:00AM	Scilex Holding Company announces successful FDA audit of enhanced ZTlido manufacturing facility in Japan (GlobeNewswire) -10.71%
Nov-28-23 09:00AM	Scilex Holding Company announces pharmacy initiative to stock ELYXYB in over 500 stores for a leading pharmacy chain in the U.S. (GlobeNewswire) -6.25%
Nov-27-23 09:00AM	Scilex Holding Company announces completion of commercial manufacturing of Gloperba with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024 (GlobeNewswire) +13.39%
Nov-22-23 09:00AM	Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy (GlobeNewswire) +6.59%
Nov-21-23 09:00AM	Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB (GlobeNewswire) -13.85%
Nov-17-23 09:00AM	Scilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch (GlobeNewswire)
Nov-15-23 09:00AM	Scilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch (GlobeNewswire)
Nov-02-23 09:00AM	Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica) (GlobeNewswire)
09:00AM	Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido , in Treatment of Musculoskeletal Pain Disorders (GlobeNewswire)
Nov-01-23 09:00AM	Scilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended October 2023, And Year-To-Date Through October 31, 2023, Based On Currently Available Information (GlobeNewswire)
Oct-27-23 03:38PM	UPDATE -- Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure (GlobeNewswire)
02:05PM	Scilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure (GlobeNewswire)
Oct-26-23 06:12AM	SCLX: An Innovative and Growing Pain Management Company (Zacks) -5.42%
Oct-09-23 02:55PM	Why Shares of Scilex Are Up Monday (Motley Fool) +15.92%
Oct-07-23 07:27PM	Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price (GlobeNewswire)
Oct-04-23 12:59PM	Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company (GlobeNewswire) +11.90%
Oct-03-23 09:00AM	Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company (GlobeNewswire) -5.26%
Sep-27-23 09:00AM	Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401) (GlobeNewswire)
Sep-25-23 09:00AM	Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023 (GlobeNewswire)
Sep-22-23 11:38AM	Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company (PR Newswire) -9.71%
Sep-21-23 04:05PM	Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc. (GlobeNewswire)
Sep-14-23 09:00AM	Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP) (GlobeNewswire)
Sep-13-23 09:00AM	Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder (GlobeNewswire) -8.61%
Sep-12-23 05:34PM	Sorrento Stock Deal Emerges Days Before It Runs Out of Cash (Bloomberg)
09:00AM	Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV (GlobeNewswire)
09:00AM	Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV (GlobeNewswire)
Sep-11-23 09:00AM	Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information (GlobeNewswire) -5.12%
Jul-27-23 09:00AM	Sorrento Issues a FAQ in Response to Large Number Of Urgent Requests from Scilex Dividend Short Holders and/or Record Holders (GlobeNewswire)
Jul-21-23 05:53PM	/C O R R E C T I O N -- Sorrento Therapeutics, Inc./ (PR Newswire) -5.08%

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Followwill Dorman	Director	Oct 18 '24	Buy	0.99	1,000	990	2,300	Oct 18 04:29 PM
Chun Jay	Director	Oct 18 '24	Buy	0.95	5,000	4,750	112,500	Oct 18 04:29 PM
Wu Yue Alexander	Director	Oct 17 '24	Buy	0.95	20,000	18,992	25,000	Oct 18 09:14 AM
Lemus David	Director	Oct 17 '24	Buy	0.90	2,000	1,800	2,000	Oct 18 09:10 AM
Ji Henry	Executive Chairperson	Oct 17 '24	Buy	0.97	10,000	9,710	60,070	Oct 18 09:08 AM
SHAH JAISIM	See Remarks	Oct 16 '24	Buy	0.99	30,000	29,751	77,333	Oct 17 12:44 PM
Ma Stephen Hoi	Chief Financial Officer	Oct 16 '24	Buy	0.97	6,700	6,499	22,840	Oct 17 11:09 AM
Followwill Dorman	Director	Jun 26 '24	Option Exercise	1.37	1,000	1,370	1,300	Jun 26 09:31 PM
Wu Yue Alexander	Director	Jun 20 '24	Option Exercise	1.41	5,000	7,050	5,000	Jun 20 06:07 PM
Ma Stephen Hoi	Chief Financial Officer	Jun 20 '24	Option Exercise	1.41	2,000	2,820	16,140	Jun 20 04:54 PM
Chun Jay	Director	Jun 20 '24	Option Exercise	1.41	5,000	7,050	107,500	Jun 20 04:49 PM
SHAH JAISIM	See Remarks	Jun 20 '24	Option Exercise	1.73	14,000	24,220	47,333	Jun 20 04:43 PM
Ji Henry	Executive Chairperson	Jun 18 '24	Option Exercise	1.41	6,000	8,460	311,273	Jun 18 09:26 PM
SHAH JAISIM	See Remarks	Jun 14 '24	Option Exercise	1.41	33,333	47,000	33,333	Jun 14 04:02 PM
Ji Henry	Executive Chairperson	May 17 '24	Buy	0.88	50,000	43,985	50,070	May 17 06:42 PM
Chun Jay	Director	May 17 '24	Buy	0.90	57,500	51,641	102,500	May 17 06:41 PM
SHAH JAISIM	See Remarks	May 16 '24	Buy	0.84	83,061	69,846	98,943	May 17 05:36 PM
SHAH JAISIM	See Remarks	May 17 '24	Buy	0.92	56,939	52,099	155,882	May 17 05:36 PM
Ma Stephen Hoi	Chief Financial Officer	May 17 '24	Buy	0.88	14,140	12,443	14,140	May 17 04:29 PM

CELU

Celularity Inc

SCLX

Scilex Holding Company

Upgrade your FINVIZ experience